MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 534802 | Name: Sobuzoxane

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Sobuzoxane is used in treatment of leukemia L1210.

Chemical Structure

Sobuzoxane
Sobuzoxane
CAS#98631-95-9

Theoretical Analysis

MedKoo Cat#: 534802

Name: Sobuzoxane

CAS#: 98631-95-9

Chemical Formula: C22H34N4O10

Exact Mass: 514.2275

Molecular Weight: 514.53

Elemental Analysis: C, 51.36; H, 6.66; N, 10.89; O, 31.09

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Sobuzoxane
IUPAC/Chemical Name
4,4'-Ethylenebis(1-(hydroxymethyl)-2,6-piperazinedione) bis(isobutyl carbonate) (ester)
InChi Key
OCOKWVBYZHBHLU-UHFFFAOYSA-N
InChi Code
InChI=1S/C22H34N4O10/c1-15(2)11-33-21(31)35-13-25-17(27)7-23(8-18(25)28)5-6-24-9-19(29)26(20(30)10-24)14-36-22(32)34-12-16(3)4/h15-16H,5-14H2,1-4H3
SMILES Code
O=C(CN(CCN(C1)CC(N(COC(OCC(C)C)=O)C1=O)=O)C2)N(COC(OCC(C)C)=O)C2=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 514.53 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Reimerová P, Jirkovská A, Piskáčková HB, Karabanovich G, Roh J, Šimůnek T, Štěrbová-Kovaříková P. UHPLC-MS/MS method for analysis of sobuzoxane, its active form ICRF-154 and metabolite EDTA-diamide and its application to bioactivation study. Sci Rep. 2019 Mar 14;9(1):4524. doi: 10.1038/s41598-019-40928-5. PMID: 30872754; PMCID: PMC6418109. 2: Inoue Y, Tsukasaki K, Nagai K, Soda H, Tomonaga M. Durable remission by sobuzoxane in an HIV-seronegative patient with human herpesvirus 8-negative primary effusion lymphoma. Int J Hematol. 2004 Apr;79(3):271-5. doi: 10.1532/ijh97.03107. PMID: 15168597. 3: Swift LP, Cutts SM, Nudelman A, Levovich I, Rephaeli A, Phillips DR. The cardio-protecting agent and topoisomerase II catalytic inhibitor sobuzoxane enhances doxorubicin-DNA adduct mediated cytotoxicity. Cancer Chemother Pharmacol. 2008 Apr;61(5):739-49. doi: 10.1007/s00280-007-0528-2. Epub 2007 Jun 27. PMID: 17594094. 4: Toyoda K, Abe Y, Tsuda M, Haji S, Choi I, Suehiro Y, Kiyasu J, Ohshima K, Uike N. [Successful treatment with oral low-dose sobuzoxane and etoposide combined with rituximab in an elderly patient with HHV-8-negative primary effusion lymphoma-like lymphoma]. Rinsho Ketsueki. 2014 Jul;55(7):815-9. Japanese. PMID: 25098519. 5: Sakai C, Murotani N. [Adult T-cell leukemia/lymphoma in a patient on hemodialysis-resistance to CHOP, but unexpected effect and remission achieved by sobuzoxane alone]. Gan To Kagaku Ryoho. 2010 Feb;37(2):347-50. Japanese. PMID: 20154500. 6: Dai ZQ, Xu JY, Yuan XJ, Cai JC. [Synergism of sobuzoxane in combination with doxorubicin against leukemia P388 in mice]. Zhongguo Yao Li Xue Bao. 1996 Jan;17(1):69-71. Chinese. PMID: 8737460. 7: Tsunoda S, Kobayashi H, Inoue K, Izumi T, Akutsu M, Katano S, Ueda T, Shirai T, Masuda Y, Ohmine K, Nagashima T, Ueda M, Takagi S, Muroi K, Ozawa K, Kano Y. [MTX-HOPE (methotrexate, hydrocortisone, vincristine, sobuzoxane, and etoposide) as a low-dose salvage chemotherapy for recurrent or refractory non-Hodgkin's lymphoma]. Gan To Kagaku Ryoho. 2007 Jun;34(6):885-9. Japanese. PMID: 17565251. 8: Tsukagoshi S. [A novel antitumor agent, sobuzoxane (MST-16)]. Gan To Kagaku Ryoho. 1994 Jun;21(7):1089-97. Japanese. PMID: 8002628. 9: Masaoka T, Kageyama T, Tatsumi N, Akasaka K, Yonezawa T, Sugiyama H, Kitani T, Yasunaga K, Horiuchi A, Nakayama S, et al. [Late phase II study of MST-16 (sobuzoxane) efficacy for malignant lymphoma]. Gan To Kagaku Ryoho. 1992 Mar;19(3):339-47. Japanese. PMID: 1543360. 10: Kato I, Nobuhara A, Wakasugi N. Testicular degeneration induced in rat offspring by maternal treatment with sobuzoxane. Reprod Toxicol. 1996 May- Jun;10(3):209-14. doi: 10.1016/0890-6238(96)00023-8. PMID: 8738557. 11: Furue H. [Topoisomerase inhibitors developing in Japan]. Gan To Kagaku Ryoho. 1993 Jan;20(1):42-9. Japanese. PMID: 8422186. 12: Poplawski T, Blasiak J. BCR/ABL downregulates DNA-PK(CS)-dependent and upregulates backup non-homologous end joining in leukemic cells. Mol Biol Rep. 2010 Jun;37(5):2309-15. doi: 10.1007/s11033-009-9730-0. Epub 2009 Aug 21. PMID: 19697154. 13: Tominaga T, Shimozuma K, Hasegawa K, Hayashibara K, Nakahiro K, Nakao I, Katayama K, Fukuda M, Majima H, Aoyama H, et al. [Early phase II study of MST-16 (sobuzoxane) for breast cancer]. Gan To Kagaku Ryoho. 1994 Jun;21(7):1009-15. Japanese. PMID: 8210250. 14: Fukuda M, Arimura T, Katayama K, Watanabe H. [Complete response provided by new antitumor agent, MST-16 (sobuzoxane), in a breast cancer with multiple cutaneous metastases]. Gan To Kagaku Ryoho. 1991 Aug;18(10):1709-12. Japanese. PMID: 1872628. 15: Yamada K, Ohno R, Oguri T, Kamiya O, Yokomaku S, Kobayashi M, Nishiwaki H, Tanaka M, Inagaki J, Mitomo Y, et al. [Late phase II study of MST-16 (sobuzoxane) on malignant lymphoma]. Gan To Kagaku Ryoho. 1991 Nov;18(14):2447-52. Japanese. PMID: 1952964. 16: Tominaga N, Teshima H, Hiraoka A, Masaoka T, Ariyoshi Y, Suzuki H, Kimura I, Ohnoshi T, Hayashi K, Arima T, et al. [Early phase II study of MST-16 (sobuzoxane) on malignant lymphoma]. Gan To Kagaku Ryoho. 1991 Nov;18(14):2441-6. Japanese. PMID: 1952963. 17: Hino M, Niitani H. [DNA topoisomerase inhibitor]. Nihon Rinsho. 1993 Dec;51(12):3291-300. Japanese. PMID: 8283648. 18: Andoh T, Ishida R. Catalytic inhibitors of DNA topoisomerase II. Biochim Biophys Acta. 1998 Oct 1;1400(1-3):155-71. doi: 10.1016/s0167-4781(98)00133-x. PMID: 9748552. 19: Lu DY, Lu TR. Antimetastatic activities and mechanisms of bisdioxopiperazine compounds. Anticancer Agents Med Chem. 2010 Sep;10(7):564-70. doi: 10.2174/187152010793498654. PMID: 20950258. 20: Nakayama S, Yabe H, Nagai K. [Clinical treatment of MST-16 (Sobuzoxane) for malignant lymphoma]. Gan To Kagaku Ryoho. 1991 Sep;18(12):2179-82. Japanese. PMID: 1888191.